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3 
ABSTRACT 1 
BACKGROUND: The optimal revascularization strategy for patients with left main coronary 2 
artery disease (LMCAD) and chronic kidney disease (CKD) remains unclear. 3 
OBJECTIVES: We investigated the comparative effectiveness of percutaneous coronary 4 
intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD 5 
and low or intermediate anatomical complexity according to baseline renal function from the 6 
multicenter randomized EXCEL trial. 7 
METHODS: CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 8 
m2 using the CKD-EPI equation. Acute renal failure (ARF) was defined as a serum creatinine 9 
increase of ≥5.0 mg/dL from baseline or a new requirement for dialysis. The primary composite 10 
endpoint was the composite of death, myocardial infarction (MI), or stroke at 3-year follow-up.  11 
RESULTS: CKD was present in 361 of 1,869 randomized patients (19.3%) in whom baseline 12 
eGFR was available. Patients with CKD had higher 3-year rates of the primary endpoint compared 13 
to those without CKD (20.8% vs. 13.5%; hazard ratio [HR]: 1.60; 95% confidence interval [CI]: 14 
1.22-2.09; p=0.0005). ARF within 30 days occurred more commonly in patients with compared to 15 
those without CKD (5.0% vs. 0.8%, p<0.0001), and was strongly associated with the 3-year risk of 16 
death, stroke or MI (50.7% vs. 14.4%; HR: 4.59; 95% CI: 2.73-7.73; p<0.0001). ARF occurred less 17 
commonly after revascularization with PCI compared with CABG both in patients with CKD (2.3% 18 
vs. 7.7%; HR: 0.28; 95% CI: 0.09-0.87) and in those without CKD (0.3% vs. 1.3%; HR: 0.20; 95% 19 
CI: 0.04-0.90; pinteraction=0.71). There were no significant differences in the rates of the primary 20 
composite endpoint after PCI and CABG in patients with CKD (23.4% vs. 18.1%; HR: 1.25; 95% 21 
CI: 0.79-1.98) and without CKD (13.4% vs. 13.5%; HR: 0.97; 95% CI: 0.73-1.27; pinteraction=0.38).  22 
CONCLUSIONS: Patients with CKD undergoing revascularization for LMCAD in the EXCEL 23 
trial had increased rates of ARF and reduced event-free survival. ARF occurred less frequently after 24 
PCI compared to CABG. Nonetheless, PCI and CABG resulted in non-significantly different rates 25 
of death, stroke or MI at 3 years in patients with and without CKD. 26 
4 
KEYWORDS: Left main; coronary artery disease; percutaneous coronary intervention; coronary 1 
artery bypass grafting; chronic kidney disease  2 
5 
CONDENSED ABSTRACT 1 
The optimal revascularization strategy for patients with obstructive left main coronary artery 2 
disease (LMCAD) and chronic kidney disease (CKD) remains unclear. We investigated the 3 
comparative effectiveness of percutaneous coronary intervention (PCI) with everolimus-eluting 4 
stents versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and CKD from 5 
the randomized EXCEL trial. At 3 years, there were no significant differences in the rates of death, 6 
myocardial infarction, or stroke between PCI and CABG in patients with (23.4% vs. 18.1%; HR: 7 
1.25; 95% confidence interval [CI]: 0.79–1.98) or without CKD (13.4% vs. 13.5%; HR: 0.97; 95% 8 
CI: 0.73–1.27) (pinteraction=0.38). 9 
  10 
6 
ABBREVIATIONS AND ACRONYMS 1 
ARF = acute renal failure 2 
CABG = coronary artery bypass graft 3 
CKD = chronic kidney disease 4 
CrCl = creatinine clearance 5 
EES = everolimus-eluting stents 6 
eGFR = estimated glomerular filtration rate 7 
LMCAD = left main coronary artery disease 8 
MDRD = Modification of Diet in Renal Disease 9 
PCI = percutaneous coronary intervention 10 
  11 
7 
Chronic kidney disease (CKD) is an increasingly prevalent condition and is strongly 1 
associated with increased cardiovascular morbidity and mortality (1). Renal dysfunction is 2 
associated with systemic inflammation, endothelial dysfunction, accelerated atherosclerosis, and 3 
enhanced thrombogenicity, which together heighten the risk for cardiovascular and cerebrovascular 4 
ischemic events (1-4). CKD is associated with a poor prognosis after coronary artery bypass graft 5 
surgery (CABG), due in part to the risk of acute renal failure (ARF) as well as associated 6 
comorbidities (2-4). However, the risk of ARF from contrast media, atheroemboli and other 7 
mechanisms is also increased in patients with CKD undergoing percutaneous coronary intervention 8 
(PCI) (5,6). These risks likely explain why patients with coronary artery disease (CAD) and CKD 9 
are less likely to undergo revascularization than those with normal renal function (2-4), despite 10 
observational studies suggesting a survival benefit after PCI and CABG in patients with multivessel 11 
disease and CKD (4). Few data comparing PCI and CABG in patients with CKD from prospective 12 
randomized trials are available to guide clinical decision-making in this high-risk group (7-11). We 13 
therefore examined the outcomes of patients with left main CAD (LMCAD) with and without CKD 14 
randomized to PCI with everolimus eluting-stents (EES) versus CABG in the Evaluation of 15 
XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization 16 
(EXCEL) trial (12). 17 
 18 
METHODS 19 
Study design. The EXCEL trial design and principal results have been previously reported 20 
(12,13). In brief, EXCEL was an international, open-label, multicenter randomized trial that 21 
compared PCI using cobalt–chromium fluoropolymer-based EES (Xience; Abbott Vascular, Santa 22 
Clara, CA) versus CABG in patients with LMCAD. Inclusion criteria were LM diameter stenosis of 23 
70%, as estimated visually, or stenosis of 50% to <70% if hemodynamically significant by non-24 
invasive or invasive testing, plus low or intermediate anatomical complexity of CAD as defined by 25 
a site-determined Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) score of 32. 26 
8 
Consensus among the members of the heart team for revascularization with either PCI or CABG 1 
was required. Clinical follow-up was performed at 1 month, 6 months, and 1 year and then annually 2 
through 5 years. At the time of the current analysis all patients have completed 3 years of follow-up. 3 
The investigation was approved by the ethics committee or institutional review board at each center, 4 
and all patients signed informed consent.  5 
The primary endpoint was the composite of death from any cause, stroke, or myocardial 6 
infarction (MI) at 3 years. Major powered secondary endpoints included this composite rate at 30 7 
days, and death, stroke, MI, or ischemia-driven revascularization at 3 years. Additional secondary 8 
endpoints included the components of the primary endpoint, as well as revascularization, stent 9 
thrombosis, symptomatic graft occlusion, bleeding complications, and a pre-specified composite of 10 
major adverse events occurring within 30 days. These endpoint definitions are reported elsewhere 11 
(12). Study monitors collected source documents of all primary and secondary endpoint events for 12 
adjudication by an independent clinical events committee. The extent and complexity of CAD and 13 
the SYNTAX score were also assessed by an independent angiographic core laboratory.  14 
The present study is a pre-specified subgroup analysis from the EXCEL trial comparing PCI 15 
and CABG in patients with and without CKD. CKD was defined as an estimated glomerular 16 
filtration rate (eGFR) <60 mL/min/1.73 m2 (corresponding to CKD stage 3A, 3B, 4, or 5), using the 17 
CKD-EPI equation as per the National Kidney Foundation-Kidney Disease Outcomes Quality 18 
Initiative guidelines (Supplemental Appendix Table 1) (14,15). This equation is preferentially 19 
endorsed by consensus guidelines as superior to other equations to discriminate between patients 20 
with versus without renal dysfunction and to predict adverse events in patients with CKD (16,17). 21 
ARF was defined in the protocol as a serum creatinine increase by ≥5.0 mg/dL from baseline or 22 
new requirement for dialysis (including hemodialysis, continuous veno-venous hemofiltration or 23 
peritoneal dialysis). 24 
 25 
9 
Statistical analysis. All analyses were performed in the intention-to-treat population, which 1 
included all patients according to the group to which they were randomly assigned, regardless of the 2 
treatment received. The median duration of follow-up in the current analysis was 3 years 3 
(interquartile range 3 to 3 years). Categorical variables were compared with the use of the χ2 test or 4 
Fisher exact test. Continuous variables were compared with the use of the Student t test or the 5 
Wilcoxon rank-sum test for non-normally distributed data. Event rates were based on Kaplan–Meier 6 
estimates in time-to-first-event analyses and were compared with the log-rank test. The association 7 
between baseline renal function (as a continuous variable) and the 3-year hazard of adverse events 8 
was also evaluated using a smoothing spline function. Hazard ratios (HR) with 95% confidence 9 
intervals (CI) were generated with Cox regression models with treatment as the main effect. The 10 
statistical significance of differences in the treatment effect of PCI versus CABG in patients with 11 
and without CKD was assessed in Cox regression models for the full trial population, including 12 
main effect terms (eg, CKD and assigned treatment) and interaction terms (eg, CKD × assigned 13 
treatment) for each outcome of interest. Primary analyses were performed using the CKD-EPI 14 
formula to define baseline CKD (14). For sensitivity analysis, we assessed the comparative 15 
effectiveness of PCI versus CABG implementing alternative equations to estimate baseline renal 16 
function, specifically the Modification of Diet in Renal Disease (MDRD) equation (14) and the 17 
Cockcroft-Gault equation (18). The renal function equation definitions are shown in Supplemental 18 
Appendix Table 1. A 2-sided p value of ≤0.05 was considered to indicate statistical significance. All 19 
statistical analyses were performed with the use of SAS software, version 9.4 (SAS Institute, Cary, 20 
North Carolina). 21 
 22 
RESULTS 23 
Baseline renal function was evaluable in 1,869 of 1,905 randomized patients (98.1%), among 24 
whom CKD was present in 361 (19.3%), 300 (16.1%), and 308 (16.5%) using the CKD-EPI, 25 
MDRD, and Cockcroft-Gault equations, respectively. The mean estimated eGFR using the CKD-26 
10 
EPI, MDRD, and Cockcroft-Gault equations was 77.2±19.1 mL/min/1.73 m2, 81.5±22.8 1 
mL/min/1.73 m2, and 89.5±32.4 mL/min in all patients, and 48.6±9.9 mL/min/1.73 m2, 49.2±9.7 2 
mL/min/1.73 m2, and 47.8±9.6 mL/min in patients with CKD, respectively. The distribution of 3 
baseline eGFR using the CKD-EPI equation is illustrated in Figure 1. Only 3/361 enrolled patients 4 
with CKD at baseline were on dialysis (0.8%). 5 
Baseline characteristics in patients with and without CKD estimated with the CKD-EPI 6 
equation are reported in Table 1. Patients with CKD were older, were more commonly female and 7 
had more comorbidities. Patients with CKD were also more likely to have a history of prior MI, 8 
atrial fibrillation, valvular heart disease, and lower left ventricular ejection fraction. Baseline 9 
angiographic characteristics and procedural characteristics with PCI or CABG are reported in Table 10 
2. There were no significant differences in site-reported or core laboratory-assessed SYNTAX 11 
scores between patients with and without CKD; however, patients with CKD were more likely to 12 
have diffuse or small vessel disease. There were no significant differences in the number of non-left 13 
main stented or bypassed vessels in patients with and without CKD (Table 2). Medication use at 14 
discharge and through 3 years in patients with and without CKD were similar, except for greater use 15 
of chronic oral anticoagulants in those with CKD (Supplemental Appendix Table 2). 16 
 Effect of CKD on outcomes. Patients with compared to those without CKD had higher 17 
rates of 30-day composite major adverse events, including more frequent blood transfusions, major 18 
arrhythmias, infections, sternal would dehiscence, and unplanned surgical and radiologic 19 
procedures (Supplemental Appendix Table 3). In addition, the rate of ARF was ~6 times greater in 20 
patients with CKD compared to those without (5.0% vs. 0.8%, p<0.0001). The 3-year primary 21 
composite endpoint of death, stroke, or MI was increased in patients with compared to those 22 
without CKD (Figure 2; 20.8% vs. 13.5%; hazard ratio: 1.60; 95% CI: 1.22-2.09; p=0.0005), driven 23 
by greater cardiac and non-cardiac mortality (Table 3). The rates of adverse outcomes incrementally 24 
increased as renal function worsened from eGFR >60 mL/min/1.73 m2 (no CKD) to eGFR 45 to 60 25 
mL/min/1.73 m2 (Stage 3A CKD) to eGFR<45 mL/min/1.73 m2 (Stage 3B, 4, or 5 CKD) 26 
11 
(Supplemental Appendix Table 4). When modeled as a continuous variable, progressively lower 1 
eGFR was associated with a steadily greater 3-year risk of death, stroke, or MI (HR per 10 2 
mL/min/1.73 m2 decrease: 1.09; 95% CI: 1.03-1.15; p=0.004) and all-cause death (HR per 10 3 
mL/min/1.73 m2 decrease: 1.23; 95% CI: 1.14-1.34; p<0.0001) (Figure 3A and 3B). Results were 4 
consistent using the MDRD and the Cockcroft-Gault equations (Supplemental Appendix Tables 5 5 
and 6).  6 
 PCI versus CABG in patients with and without CKD. PCI was associated with lower 30-7 
day rates of major adverse events compared with CABG, in patients with and without CKD (Table 8 
4). PCI was also associated with shorter in-hospital stay compared with CABG both in patients with 9 
CKD (6.7±7.0 vs. 16.1±15.2; p<0.0001) and without CKD (5.2±4.7 vs. 11.9±7.4; p<0.0001). At 30 10 
days, PCI compared with CABG resulted in lower rates of the composite endpoint of death, MI, or 11 
stroke both in patients with CKD (6.2% vs. 9.3%, HR: 0.68; 95% CI: 0.32-1.45) and without CKD 12 
(4.5% vs. 7.4%, HR: 0.61; 95% CI: 0.40-0.93) (pinteraction=0.80). At 3 years (Figure 4), there were no 13 
significant differences in the rates of the primary composite endpoint of death, MI, or stroke after 14 
PCI versus CABG, an effect that was consistent in patients with and without CKD (pinteraction=0.36) 15 
(Table 5). The 3-year relative rates of the components of the primary endpoint, as well as 16 
revascularization and bleeding after PCI versus CABG were also consistent in patients with and 17 
without CKD (Table 5). CABG was associated with less ischemia-driven revascularization during 18 
follow-up, the risk of which was consistent across varying levels of baseline renal function 19 
(Supplemental Appendix Table 7). In the CKD group, 3-year mortality was increased after PCI 20 
compared with CABG, due to greater non-cardiac deaths, specifically due to sepsis (5.4% vs. 1.1%; 21 
p=0.02), which occurred more than 30 days post procedure. There was no significant difference in 22 
cardiac mortality after PCI vs. CABG either in patients with or without CKD. The comparative 23 
effectiveness of PCI versus CABG on the risk of death, MI, or stroke at 30 days and 3 years was 24 
consistent across varying definitions of CKD (Figure 5). 25 
12 
 ARF and outcomes after LM revascularization. Baseline clinical and procedural 1 
characteristics which were associated with the development of ARF within 30 days are reported in 2 
Supplemental Appendix Table 8. Compared with CABG, PCI was associated with significantly 3 
lower rates of ARF at 30 days in both patients with CKD (2.3% vs. 7.6%; HR: 0.28; 95% CI: 0.09-4 
0.87) and in those without CKD (0.3% vs. 1.3%; HR: 0.20; 95% CI: 0.04-0.90; pinteraction=0.71) 5 
(Table 6). Dialysis was also required more frequently after CABG compared with PCI, regardless of 6 
baseline CKD status (pinteraction=0.87). Outcomes at 3 years in patients with versus without ARF 7 
within 30 days are reported in Supplemental Appendix Table 9. The occurrence of ARF was 8 
strongly associated with increased 3-year risk of death, stroke or MI at 3 years (50.7% vs. 14.4%; 9 
HR: 4.59; 95% CI: 2.73-7.73; p<0.0001). 10 
 11 
DISCUSSION 12 
The Central Illustration demonstrates the major findings of the present pre-specified analysis 13 
from the EXCEL trial, in which we explored the relative effects of PCI with EES versus CABG in 14 
patients with LMCAD and low or intermediate SYNTAX scores according to baseline renal 15 
function. Progressively worse renal impairment in patients undergoing LM revascularization was 16 
associated with steadily increasing rates of cardiovascular and hemorrhagic adverse events and 17 
mortality during 3 years of follow-up. Compared with CABG, PCI was associated with lower rates 18 
of ARF, including dialysis, and 30-day major adverse events in both patients with and without 19 
CKD. The occurrence of ARF at 30 days was strongly associated with increased risk of adverse 20 
events and mortality over 3 years of follow-up. At 3 years, however, there were no significant 21 
differences in the rates of death, MI, or stroke between PCI-treated and CABG-treated patients, 22 
regardless of baseline CKD. Despite the fact that definite stent thrombosis occurred less frequently 23 
than symptomatic graft failure, ischemia-driven revascularization rates at 3 years were lower after 24 
CABG compared to PCI, an effect that was consistent in patients with preserved or reduced renal 25 
13 
function. Finally, the impact of CKD, and the comparative outcomes of PCI versus CABG in 1 
patients with and without CKD were consistent irrespective of definition of renal dysfunction. 2 
Evidence from prior randomized trials to inform revascularization decisions in patients with 3 
CKD is scarce, especially in LMCAD. Among diabetic patients with CKD and non-LM multivessel 4 
disease enrolled in the Future Revascularization Evaluation in Patients with Diabetes Mellitus: 5 
Optimal Management of Multivessel Disease (FREEDOM) trial, CABG compared with PCI with 6 
paclitaxel-eluting stents resulted in a 27% relative risk reduction in major adverse cardiovascular 7 
and cerebrovascular events (MACCE) at a median follow-up of 3.8 years (7). Among CKD patients 8 
with non-LM multivessel disease enrolled in the New York State outcomes registries, PCI with EES 9 
was associated with lower rates of MACCE at 30 days than CABG, but higher rates of MI and 10 
repeat revascularization at 4 years, with similar rates of death (19). In a pooled analysis from the 11 
Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main 12 
Coronary Artery Disease (PRECOMBAT) and SYNTAX trials, PCI with first-generation 13 
paclitaxel-eluting and sirolimus-eluting stents was associated with comparable 5-year rates of 14 
MACCE and death compared with CABG in patients with LMCAD with and without CKD, without 15 
significant interaction (20).  16 
The present large-scale study in which contemporary DES and revascularization techniques 17 
were used confirms and extends these prior findings to patients with LMCAD. Patients with CKD 18 
constituted ~25% of the EXCEL trial population, in whom the mean eGFR was 48.5±9.9 19 
mL/min/1.73 m2, representing moderately severe CKD. PCI with EES in patients with LMCAD 20 
reduced 30-day periprocedural adverse events and the 30-day composite rate of death, stroke, or MI 21 
consistently in both CKD and non-CKD cohorts. Specifically, PCI resulted in reduced bleeding, 22 
need for transfusions, arrhythmias, and less ARF (including the need for dialysis) compared with 23 
CABG in patients with CKD, adverse events which have been associated with long-term mortality 24 
(21-27). In this regard, ARF in the EXCEL trial was defined as an increase in serum creatinine ≥5 25 
mg/dL or a new requirement for dialysis, corresponding to acute kidney injury of stage III or greater 26 
14 
in the most recent Kidney Disease: Improving Global Outcomes (KDIGO) classification (28). ARF 1 
as so defined was strongly associated with worse outcomes over 3 years of follow-up. The reduced 2 
rate of ARF after PCI compared with CABG in both the CKD and non-CKD cohorts is one factor 3 
that should considered when deciding between revascularization strategies to avoid further declines 4 
in renal function in patients with CKD. However, the composite 3-year primary endpoint rate of 5 
death, MI, or stroke was similar after PCI and CABG, a finding that was consistent in patients with 6 
and without CKD. The lower rates of MI and revascularization during the follow-up period after 7 
CABG compared to PCI as initially described in EXCEL (7) may have offset the deleterious effects 8 
of ARF and surgical complications in the CKD cohort. 9 
Renal dysfunction has been associated with late DES failure (29-31). Nonetheless, the 3-year 10 
rates of definite EES thrombosis were lower than the rates of symptomatic graft occlusion in 11 
patients with and without CKD, and ischemia-driven revascularization after EES within 3 years was 12 
required in only 10.9% of patients with CKD compared to 13.0% of patients without CKD. These 13 
observations demonstrate that the anti-thrombotic and anti-restenotic properties of EES are 14 
preserved in higher-risk CKD patients and lesions (32,33). It thus follows that improved chronic 15 
medical therapy regimens are required to slow progressive atherosclerosis if the long-term 16 
prognosis of high-risk CKD patients is to be improved after PCI (and CABG). Toward this end 17 
insights may be gained from the ongoing International Study of Comparative Health Effectiveness 18 
With Medical and Invasive Approaches–Chronic Kidney Disease (ISCHEMIA-CKD) trial 19 
[NCT01985360] in which patients with stable ischemic heart disease and advanced CKD 20 
(eGFR<30 mL/min/1.73 m2 or dialysis) are being assigned to an invasive revascularization strategy 21 
versus initial medical management. 22 
 Limitations. First, although the present study was pre-specified, the CKD and non-CKD 23 
subgroups were not individually powered to draw definitive conclusions as to whether PCI or 24 
CABG should be favored. Randomization was not stratified by renal function, and the role of 25 
unmeasured confounders cannot be excluded. Our findings should thus be considered hypothesis-26 
15 
generating. Second, while some patients with severe CKD were included, the majority had 1 
moderate renal impairment. Therefore, our findings cannot be extrapolated to a severe CKD and 2 
end-stage renal disease population. Third, EXCEL enrolled patients with LMCAD and site-assessed 3 
low and intermediate anatomical complexity. Our findings therefore do not apply to patients with 4 
CAD and extreme anatomic complexity. Nonetheless, the mean core laboratory-assessed SYNTAX 5 
score in the EXCEL trial of 26.5 was roughly comparable to that from the FREEDOM trial (mean 6 
26.2) and the SYNTAX trial (mean 28.8), implying that the present results may inform outcomes in 7 
patients with more extensive CAD. Finally, follow-up in EXCEL is complete through only 3 years. 8 
Longer-term follow-up (currently planned for 5 years) is required to determine whether additional 9 
late differences between PCI and CABG emerge. 10 
 Conclusions. In patients with LMCAD and site-assessed low or intermediate SYNTAX 11 
scores undergoing revascularization, the presence of CKD was associated with a substantially 12 
greater risk of periprocedural adverse events and mortality during 3-year follow-up. Although PCI 13 
with EES was associated with significantly lower 30-day rates of ARF and major adverse events 14 
compared with CABG, there were no significant differences between the revascularization 15 
modalities for the primary composite endpoint or components of death, MI, or stroke at 3 years, 16 
with no interaction according to baseline CKD status. Both PCI and CABG are thus acceptable 17 
revascularization approaches in selected high-risk patients with LMCAD and CKD. Individual 18 
patient comorbidities, the likelihood to safely obtain complete revascularization, and patient 19 
preferences as to the early benefits of PCI versus the late benefits of CABG should thus be factored 20 
into the heart team decision-making process in high-risk patients with LMCAD and CKD. 21 
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CLINICAL PERSPECTIVES 1 
 Competency in Medical Knowledge (1): Patients with CKD and LMCAD undergoing 2 
revascularization are at substantially greater risk for ARF, periprocedural adverse events, 3 
and mortality over 3 years of follow-up. 4 
 Competency in Medical Knowledge (2): PCI with EES in patients with CKD and LMCAD 5 
with site-assessed low or intermediate anatomical complexity is associated with lower rates 6 
of 30-day adverse events including ARF, major bleeding, and arrhythmias compared with 7 
CABG. Over 3 years of follow-up, PCI and CABG resulted in comparable rates of death, 8 
MI, or stroke, irrespective of baseline renal function. 9 
 Competency in Patient Care: Both PCI and CABG are acceptable revascularization 10 
strategies for high-risk patients with CKD and LMCAD. Individual patient comorbidities, 11 
patient preferences, and the early benefits of PCI versus the late benefits of CABG should be 12 
taken into account by the heart team when deciding between the two revascularization 13 
strategies.  14 
 Translational Outlook: Improved chronic medical therapy regimens are required to slow 15 
progressive atherosclerosis if the long-term prognosis of high-risk CKD patients is to be 16 
improved after PCI and CABG. 17 
  18 
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FIGURE LEGENDS 1 
FIGURE 1. Distribution of the Estimated Glomerular Filtration Rate in the EXCEL Trial 2 
Population Using The CKD-EPI Equation. 3 
The left y-axis refers to the histogram of the number of patients with estimated glomerular filtration 4 
rate (eGFR) per 5 mL/min/1.73 m2 increments. The right y-axis refers to the cumulative frequency 5 
distribution curve of eGFR values. The median [25%, 75%] eGFR was 79.2 [64.0, 91.3] 6 
mL/min/1.73 m2 and the mean  SD eGFR was 77.219.1 mL/min/1.73 m2 (range 6.5–139.2 7 
mL/min/1.73 m2). 8 
 9 
FIGURE 2. Three-Year Outcomes in Patients With Versus Without Chronic Kidney Disease. 10 
Kaplan-Meier time-to-first event curves for death, myocardial infarction, or stroke during 3 years of 11 
follow-up in patients with and without chronic kidney disease (CKD). CI = confidence interval; 12 
GFR = glomerular filtration rate; HR = hazard ratio. 13 
 14 
FIGURE 3. Risk of Adverse Events According to Baseline Renal Function. 15 
Smooth hazard function for the risk of (A) death, myocardial infarction, or stroke, and (B) death at 16 
3 years according to baseline renal function estimated with the CKD-EPI equation. CABG = 17 
coronary artery bypass grafting; CI = confidence interval; eGFR = estimated glomerular filtration 18 
rate; PCI = percutaneous coronary intervention.  19 
 20 
FIGURE 4. Three-Year Outcomes in with PCI Versus CABG in Patients With or Without 21 
Chronic Kidney Disease. 22 
Kaplan-Meier time-to-first event curves for death, myocardial infarction, or stroke during 3 years of 23 
follow-up according to randomized treatment with percutaneous coronary intervention (PCI) versus 24 
coronary artery bypass grafting (CABG) in patients with and without CKD. CI = confidence 25 
interval; GFR = glomerular filtration rate; HR = hazard ratio. 26 
22 
FIGURE 5. Thirty-Day and Three-Year Outcomes for Percutaneous Coronary Intervention 1 
Versus Coronary Artery Bypass Grafting Using Alternative Chronic Kidney Disease 2 
Equations. 3 
CABG = coronary artery bypass grafting; CKD = chronic kidney disease; CKD-EPI = CKD 4 
Epidemiology Collaboration; CrCl = creatinine clearance; MDRD = Modification of Diet in Renal 5 
Disease; MI = myocardial infarction; PCI = percutaneous coronary intervention. 6 
 7 
CENTRAL ILLUSTRATION. Risk and Benefits of Percutaneous Coronary Intervention 8 
Versus Coronary Artery Bypass Graft Surgery in Patients With Chronic Kidney Disease and 9 
Left Main Coronary Artery Disease With Site-Assessed Low or Intermediate SYNTAX 10 
Scores. 11 
ARF = Acute Renal Failure; CABG = coronary artery bypass grafting; MI = myocardial infarction; 12 
PCI = percutaneous coronary intervention. 13 
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TABLE 1. Baseline Characteristics. 1 
 Chronic Kidney 
Disease 
(n = 361) 
No Chronic Kidney 
Disease 
(n = 1508) 
p-value 
Age, years 72.7 ± 7.8 64.3 ± 9.2 <0.0001 
Male sex 239/361 (66.2%) 1200/1508 (79.6%) <0.0001 
Medical history    
  Hypertension 306/361 (84.8%) 1073/1508 (71.2%) <0.0001 
  Hyperlipidemia 266/360 (73.9%) 1038/1506 (68.9%) <0.0001 
  Current smoker 44/359 (12.3%) 365/1497 (24.4%) <0.0001 
  Prior stroke or transient ischemic attack 37/361 (10.2%) 80/1507 (5.3%) 0.0005 
  Congestive heart failure 43/361 (11.9%) 79/1503 (5.3%) <0.0001 
  Diabetes mellitus 146/361 (40.4%) 403/1508 (26.7%) <0.0001 
Insulin-treated 46/361 (12.7%) 101/1508 (6.7%)  
  Peripheral artery disease 48/359 (13.4%) 131/1503 (8.7%) 0.007 
  Chronic obstructive pulmonary disease 29/361 (8.0%) 115/1505 (7.6%) 0.80 
  Anemia 61/358 (17.0%) 121/1505 (8.0%) <0.0001 
  Carotid artery disease 45/359 (12.5%) 109/1502 (7.3%) 0.001 
  On dialysis 3/361 (0.8%) - - 
Cardiac history    
  Prior percutaneous coronary intervention 70/360 (19.4%) 249/1507 (16.5%) 0.19 
  Prior myocardial infarction 77/357 (21.6%) 246/1497 (16.4%) 0.02 
  Atrial fibrillation 29/361 (8.0%) 42/1508 (2.8%) <0.0001 
  Any baseline mitral regurgitation* 115/327 (35.2%) 400/1405 (28.5%) 0.02 
  Any baseline aortic regurgitation* 47/325 (14.5%) 143/1401 (10.2%) 0.03 
  Any baseline tricuspid regurgitation* 94/323 (29.1%) 355/1392 (25.5%) 0.18 
  Left ventricular ejection fraction, % 55.5 ± 10.6 57.5 ± 8.9 0.002 
Clinical presentation    
  Stable angina 189/360 (52.5%) 799/1502 (53.2%) 0.81 
  Unstable angina 87/360 (24.2%) 370/1502 (24.6%) 0.85 
  Non–STEMI† 43/357 (12.0%) 199/1498 (13.3%) 0.52 
  STEMI† 5/357 (1.4%) 22/1498 (1.5%) 0.92 
Laboratory measures    
  HbA1c, % 6.4 ± 1.3 6.2 ± 1.2 <0.0001 
  White blood cell count, ×109/L 7.8 ± 2.1 7.8 ± 2.1 0.81 
  Hemoglobin, g/dL 12.7 ± 1.7 13.8 ± 1.5 <0.0001 
  Platelet count, ×109/L 231.6 ± 71.5 226.8 ± 62.4 0.47 
  Brain natriuretic peptide, mg/L 450.8 ± 981.9 202.2 ± 453.5 <0.0001 
  High-sensitivity C-reactive protein, mg/L 9.1 ± 15.2 6.3 ± 12.6 0.001 
  Serum creatinine, mg/dL 1.4 ± 0.7 0.9 ± 0.2 <0.0001 
Values are n/N (%) or mean ± standard deviation, as appropriate. *All were moderate or less; severe valve disease 2 
was an exclusion criterion; †within 7 days before randomization. STEMI = ST-segment elevation myocardial 3 
infarction. 4 
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TABLE 2. Angiographic and Procedural Characteristics in Patients With Versus Without CKD. 1 
 
Chronic Kidney 
Disease 
(n = 361) 
No Chronic Kidney 
Disease 
(n = 1508) 
p-value 
Baseline angiographic characteristics    
SYNTAX score, site-reported 21.0 ± 6.0 20.4 ± 6.2 0.11 
  Low complexity (<23) 211/361 (58.4%) 917/1506 (60.9%)  
  Intermediate complexity (23-32) 150/361 (41.6%) 589/1506 (39.1%)  
SYNTAX score, core laboratory assessed 26.5 ± 8.7 26.5 ± 9.4 0.63 
  Low complexity (<23) 111/348 (31.9%) 534/1457 (36.7%)  
  Intermediate complexity (23-32) 157/348 (45.1%) 568/1457 (39.0%)  
  High complexity (>32) 80/348 (23.0%) 355/1457 (24.4%)  
Left main diameter stenosis, % 75.7 ± 12.4 75.3 ± 12.0 0.60 
Bifurcation or trifurcation disease of the distal left 
main segment 
275/352 (78.1%) 1212/1491 (81.3%) 0.18 
Number of non-left main diseased vessels    
  0 49/352 (13.9%) 276/1491 (18.5%) 0.04 
  1 117/352 (33.2%) 455/1491 (30.5%) 0.32 
  2 122/352 (34.7%) 491/1491 (32.9%) 0.54 
  3 64/352 (18.2%) 269/1491 (18.0%) 0.95 
Diffuse or small vessel disease 36/356 (10.1%) 76/1482 (5.1%) 0.0004 
PCI characteristics    
Non-left main lesions stented per patient    
   Left anterior descending artery 57/172 (33.1%) 207/750 (27.6%) 0.15 
   Left circumflex artery 31/172 (18.0%) 122/750 (16.3%) 0.58 
   Right coronary artery 41/172 (23.8%) 203/750 (27.1%) 0.39 
Number of any stented lesions per patient 2.0 ± 1.1 1.9 ± 1.1 0.34 
Number of any stented vessels per patient 1.7 ± 0.8 1.7 ± 0.8 0.55 
Number of stents implanted per patient 2.6 ± 1.5 2.4 ± 1.5 0.09 
Total stent length, per patient 50.9 ± 35.6 48.8 ± 35.8 0.27 
Intravascular imaging used 133/172 (77.3%) 579/750 (77.2%) 0.97 
Fractional flow reserve used 13/171 (7.6%) 70/750 (9.3%) 0.48 
Time in the catheterization laboratory, min 112.6 ± 53.1 111.0 ± 52.5 0.81 
CABG characteristics    
Coronary segments of distal anastomosis (CASS)    
   Left anterior descending artery 174/176 (98.9%) 718/727 (98.8%) 1.00 
   Left circumflex artery 154/176 (87.5%) 644/727 (88.6%) 0.69 
   Right coronary artery 73/176 (41.5%) 268/727 (36.9%) 0.26 
Number of vessels bypassed per patient 2.3 ± 0.6 2.2 ± 0.5 0.41 
Number of conduits per patient 2.6 ± 0.8 2.6 ± 0.8 0.16 
Number of arterial conduits per patient 1.3 ± 0.6 1.4 ± 0.6 0.31 
Number of venous conduits per patient 1.3 ± 0.9 1.2 ± 1.0 0.10 
Bypass duration, min 77.2 ± 33.1 85.3 ± 48.1 0.17 
Time in the operating room, min 291.0 ± 76.6 282.9 ± 75.0 0.11 
Values are n/N (%) or mean ± standard deviation, as appropriate. CASS = Coronary Artery Surgery Study. 2 
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TABLE 3. Three-Year Outcomes in Patients With Versus Without Chronic Kidney Disease 
 
Chronic Kidney 
Disease 
(n = 361) 
No Chronic 
Kidney Disease 
(n = 1508) 
Hazard Ratio 
(95% Confidence Interval) 
p-value 
Death, stroke, or myocardial infarction 20.8% (73) 13.5% (200) 1.60 (1.22-2.09) 0.0005 
  Death 12.9% (45) 5.4% (80) 2.48 (1.72-3.57) <0.0001 
    Cardiac death 7.3% (25) 3.3% (48) 2.27 (1.40-3.69) 0.0006 
    Non-cardiac death 6.0% (20) 2.2% (32) 2.78 (1.59-4.86) 0.0002 
  Stroke 3.6% (12) 2.5% (36) 1.46 (0.76-2.80) 0.26 
  Myocardial infarction 9.0% (31) 8.0% (118) 1.13 (0.76-1.68) 0.54 
Death, stroke, myocardial infarction, or ischemia-driven 
revascularization 
24.2% (85) 19.9% (296) 1.25 (0.98-1.59) 0.07 
  Ischemia-driven revascularization 8.6% (29) 10.3% (149) 0.85 (0.57-1.26) 0.42 
Stent thrombosis, definite or probable 1.1% (4) 0.6% (9) 1.93 (0.59-6.26) 0.27 
Graft stenosis or occlusion 2.3% (8) 2.7% (39) 0.89 (0.42-1.90) 0.76 
Definite stent thrombosis or symptomatic graft occlusion 2.6% (9) 3.1% (45) 0.87 (0.42-1.78) 0.70 
TIMI major or minor bleeding 11.1% (39) 6.9% (103) 1.61 (1.12-2.33) 0.01 
Values are Kaplan-Meier estimate (number of events). TIMI = Thrombolysis in Myocardial Infarction. 
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TABLE 4. Thirty-Day Major Adverse Events After PCI Versus CABG in Patients With Versus Without Chronic Kidney Disease 
 Chronic Kidney Disease (n = 361)  No Chronic Kidney Disease (n = 1508) 
 PCI 
(n = 177) 
CABG 
(n = 184) 
Hazard Ratio 
(95% CI) 
p-value 
 PCI 
(n = 757) 
CABG 
(n = 751) 
Hazard Ratio 
(95% CI) 
p-value 
Major adverse events, any 10.9% (19) 29.8% (54) 0.36 (0.23-0.59) <0.0001  6.2% (47) 21.5% (160) 0.29 (0.21-0.39) <0.0001 
  Death 1.1% (2) 1.7% (3) 0.69 (0.12-4.08) 1.00  0.3% (2) 1.1% (8) 0.25 (0.05-1.16) 0.06 
  Myocardial infarction 4.0% (7) 6.6% (12) 0.60 (0.24-1.50) 0.27  3.4% (26) 5.9% (44) 0.58 (0.36-0.94) 0.02 
  Stroke 1.1% (2) 1.7% (3) 0.69 (0.12-4.08) 1.00  0.3% (2) 1.3% (10) 0.20 (0.04-0.90) 0.02 
  Transfusion of ≥2 units blood 6.3% (11) 24.3% (44) 0.26 (0.14-0.48) <0.0001  2.7% (20) 15.6% (116) 0.17 (0.11-0.27) <0.0001 
  TIMI major or minor bleeding 3.4% (6) 12.2% (22) 0.28 (0.12-0.68) 0.002  2.7% (20) 8.7% (65) 0.30 (0.19-0.50) <0.0001 
  Major arrhythmia 2.3% (4) 19.9% (36) 0.11 (0.04-0.32) <0.0001  1.7% (13) 13.6% (101) 0.13 (0.07-0.22) <0.0001 
  Unplanned coronary 
revascularization for ischemia 
1.1% (2) 2.2% (4) 0.52 (0.10-2.79) 0.69  0.1% (1)  1.1% (8) 0.12 (0.02-0.98) 0.02 
  Any unplanned surgery or 
therapeutic radiologic procedure 
0.6% (1) 8.3% (15) 0.07 (0.01-0.52) 0.0004  0.9% (7) 2.7% (20) 0.34 (0.15-0.81) 0.01 
  Acute renal failure* 2.3% (4) 7.7% (14) 0.30 (0.10-0.88) 0.02  0.3% (2) 1.2% (9) 0.22 (0.05-1.01) 0.03 
  Sternal wound dehiscence 0.0% (0) 3.3% (6) 0.08 (0.00-1.40) 0.03  0.0% (0) 0.4% (3) 0.14 (0.01-2.72) 0.12 
  Infection requiring antibiotics  2.3% (4) 11.6% (21) 0.20 (0.07-0.56) 0.0006  0.8% (6) 8.2% (61) 0.10 (0.04-0.22) <0.0001 
  Intubation for >48 hours 0.6% (1) 3.9% (7) 0.15 (0.02-1.19) 0.07  0.4% (3) 2.4% (18) 0.16 (0.05-0.56) 0.0009 
  Post-pericardiotomy syndrome 0.0% (0)  0.0% (0) — —  0.0% (0) 0.3% (2) 0.20 (0.01-4.10) 0.25 
*Defined as a serum creatinine increase of ≥5.0 mg/dL from baseline or a new requirement for dialysis. CABG = coronary artery bypass graft; CI = confidence interval; PCI = percutaneous 
coronary intervention; TIMI = Thrombolysis in Myocardial Infarction. 
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TABLE 5. Three-Year Outcomes for PCI Versus CABG in Patients With or Without Chronic Kidney Disease 
 Chronic Kidney Disease (n = 361)  No Chronic Kidney Disease (n = 1508) 
Pinteraction  PCI 
(n = 177) 
CABG                     
(n = 184) 
Hazard Ratio 
(95% CI) 
 PCI 
(n = 757) 
CABG 
(n = 751) 
Hazard Ratio 
(95% CI) 
Death, stroke, or myocardial infarction 23.1% (40) 18.4% (33) 1.25 (0.79-1.98)  13.4% (100) 13.5% (100) 0.97 (0.73-1.27) 0.36 
  Death 16.9% (29) 9.0% (16) 1.91 (1.04-3.52)  5.9% (44) 4.9% (36) 1.19 (0.77-1.85) 0.22 
    Cardiac 8.3% (14) 6.2% (11) 1.34 (0.61-2.94)  3.5% (26) 3.0% (22) 1.15 (0.65-2.04) 0.77 
    Non-cardiac 9.2% (15) 2.9% (5) 3.15 (1.15-8.68)  2.5% (18) 2.0% (14) 1.25 (0.62-2.52) 0.14 
  Stroke 3.1% (5) 4.0% (7) 0.75 (0.24-2.36)  2.2% (16) 2.8% (20) 0.78 (0.40-1.50) 0.95 
  Myocardial infarction 9.5% (16) 8.4% (15) 1.11 (0.55-2.24)  7.7% (57) 8.3% (61) 0.91 (0.63-1.30) 0.62 
Death, stroke, myocardial infarction, or IDR 27.2% (47) 21.2% (38) 1.28 (0.84-1.97)  21.8% (163) 18.0% (133) 1.20 (0.95-1.50) 0.77 
  IDR 10.9% (18) 6.4% (11) 1.74 (0.82-3.68)  13.0% (95) 7.5% (54) 1.75 (1.25-2.44) 0.96 
Stent thrombosis, definite or probable 2.3% (4) — —  1.2% (9) — — — 
Graft occlusion, symptomatic — 4.5% (8) —  — 5.4% (39) — — 
Definite stent thrombosis or symptomatic graft 
occlusion 
0.6% (1) 4.5% (8) 0.13 (0.02-1.03)  0.8% (6) 5.4% (39) 0.15 (0.06-0.35) 0.91 
TIMI major or minor bleeding 8.3% (14) 13.8% (25) 0.57 (0.29-1.09)  4.8% (36) 9.0% (67) 0.52 (0.35-0.78) 0.80 
Values are Kaplan-Meier estimate (number of events). CABG = coronary artery bypass graft; CI = confidence interval; CKD = chronic kidney disease; IDR = ischemia-driven revascularization; PCI 
= percutaneous coronary intervention; TIMI = Thrombolysis in Myocardial Infarction. 
 
 
28 
TABLE 6. Acute renal failure at 30 days in patients with or without CKD undergoing PCI versus CABG. 
 Chronic Kidney Disease (n = 361)  No Chronic Kidney Disease (n = 1508) 
pinteraction 
 
PCI 
(n = 177) 
CABG 
(n = 184) 
Hazard Ratio 
(95% CI) 
 
PCI 
(n = 757) 
CABG 
(n = 751) 
Hazard Ratio 
(95% CI) 
Acute renal failure† 2.3% (4) 7.6% (14) 0.28 (0.09-0.87)  0.3% (2) 1.3% (10) 0.20 (0.04-0.90) 0.71 
New requirement for dialysis 1.1% (2) 5.4% (10) 0.20 (0.04-0.92)  0.1% (1) 0.5% (4) 0.25 (0.03-2.22) 0.87 
Hemodialysis 0.6% (1) 2.7% (5) 0.20 (0.02-1.76)  0.1% (1)* 0.4% (3) 0.33 (0.03-3.18) 0.76 
CVVH 0.6% (1) 2.7% (5) 0.20 (0.02-1.76)  0.1% (1)* 0.1% (1) 0.99 (0.06-15.89) 0.38 
†Defined as the rise in serum creatinine >5 mg/dL or a new requirement for dialysis. *One patient in the no chronic kidney disease group had both CVVH and hemodialysis. CVVH: 
Continuous veno-venous hemofiltration. 
